Tafenoquine Oral Tablet

DRUG3 trials

Sponsors

60 Degrees Pharmaceuticals LLC, 60P Australia Pty Ltd, State University of New York - Upstate Medical University

Conditions

COVID 19 DiseaseInfectious DiseaseMild to Moderate COVID 19 DiseasePharmacokinetic in Normal PopulationSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2

Early Phase 1

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

Not yet recruitingNCT07373743

State University of New York - Upstate Medical UniversityPharmacokinetic in Normal Population

Start: 2026-05-01End: 2027-03-01Target: 20Updated: 2026-03-20

Phase 2

Tafenoquine in Patients With Mild to Moderate COVID-19

CompletedNCT04533347

60 Degrees Pharmaceuticals LLCCOVID 19 Disease

Start: 2021-02-19End: 2022-06-30Updated: 2025-01-07

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

60P Australia Pty LtdCOVID 19 Disease, Infectious Disease, Mild to Moderate COVID 19 Disease +2

Start: 2023-08-01End: 2024-04-27Target: 148Updated: 2023-07-17